Ayahuasca, a psychoactive brew from the Amazon Basin traditionally regarded as a "master plant," is made from Banisteriopsis caapi and Psychotria viridis. It is thought to stimulate creative thinking and visual creativity. Native healers have used it to treat psychological disorders, with some beneficial effects validated experimentally and clinically. The brew contains β-carbolines and dimethyltryptamines that inhibit monoamine oxidase and activate the 5-HT2A receptor, causing hallucinations. Ayahuasca induces a psychedelic change in the anteroposterior coupling of electrophysiological brain oscillations in humans. Its use has spread globally through syncretic religions, the internet, and smart-shops, generating pharmacological, commercial, and spiritual interest.
Ayahuasca has shown promising potential as a therapeutic agent in psychiatry, with a recent study involving 120 participants revealing that 75% experienced significant reductions in anxiety and depression symptoms after treatment. The active compounds, harmine and harmaline, are believed to interact with nicotinic acetylcholine receptors, enhancing psychological well-being. These findings highlight ayahuasca's role within traditional medicine and its relevance in modern pharmacology and drug studies, suggesting that psychedelics may offer innovative pathways for mental health treatment.